8 articles found
FDA clears IND application for ANS-858, a first-in-class ALDH2 inhibitor targeting pathological craving in alcohol and substance use disorders, clearing path to Phase 1 trials.
The VA's CRAVE trial will enroll more than 600 veterans at 18 medical centers to test whether weekly semaglutide injections can treat alcohol use disorder.
Phase 2 RECLAIM trial shows pemvidutide significantly reduces heavy drinking days in alcohol use disorder patients, offering hope for 28 million Americans.
Landmark BMJ study of 600,000+ veterans finds GLP-1 medications like Ozempic and Wegovy associated with 14-25% lower risk of developing substance use disorders, including alcohol, opioids, and stimulants.
Washington University study of 600,000 veterans finds GLP-1 medications like Ozempic and Wegovy associated with reduced risks of substance use disorders and fewer overdoses across alcohol, opioids, nicotine, and other drugs.
The Department of Veterans Affairs begins first government-sponsored study of MDMA-assisted therapy, enrolling 80 veterans in groundbreaking research on psychedelic treatment for co-occurring conditions.
Clinical trial shows semaglutide plus cognitive behavioral therapy significantly reduces alcohol consumption, offering new hope for treating alcohol use disorder with existing medications.
New BMJ research finds semaglutide and similar medications associated with 14% reduced risk of developing substance use disorders and 50% fewer deaths among veterans already in treatment.